BACKGROUND: The association between HER2 Ile655Val single nucleotide polymorphism and cancer is controversial. OBJECTIVES: The aim of our study was to investigate this polymorphism in patients with ovarian cancer. PATIENTS AND METHODS: Genomic DNA was extracted from peripheral blood leukocytes of 107 patients and 130 healthy women. HER2 gene polymorphism was assessed by PCR-RFLP. RESULTS: No significant difference was observed in genotype and allele frequency between patient and control groups according to HER2 Ile655Val polymorphism. The disease stage, age, and histological type were also not associated with the polymorphism. CONCLUSIONS: Our data showed that HER2 Ile655Val single nucleotide polymorphism was not significantly associated with onset, histological type, age, and stage of ovarian cancer in Iranian patients.
BACKGROUND: The association between HER2Ile655Val single nucleotide polymorphism and cancer is controversial. OBJECTIVES: The aim of our study was to investigate this polymorphism in patients with ovarian cancer. PATIENTS AND METHODS: Genomic DNA was extracted from peripheral blood leukocytes of 107 patients and 130 healthy women. HER2 gene polymorphism was assessed by PCR-RFLP. RESULTS: No significant difference was observed in genotype and allele frequency between patient and control groups according to HER2Ile655Val polymorphism. The disease stage, age, and histological type were also not associated with the polymorphism. CONCLUSIONS: Our data showed that HER2Ile655Val single nucleotide polymorphism was not significantly associated with onset, histological type, age, and stage of ovarian cancer in Iranian patients.
Entities:
Keywords:
Carcinoma, Endometrioid; HER2; Polymorphism, Single Nucleotide
Authors: Rafał Watrowski; Dan Cacsire Castillo-Tong; Eva Schuster; Michael B Fischer; Paul Speiser; Robert Zeillinger Journal: Tumour Biol Date: 2015-12-14